Antoinette Pinto
Cardiovascular Disease · New Hyde Park, NYNPI 1851952212
Payments from drug & device makers
Across 106 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$513
- Amgen$250
- Novo Nordisk$220
- Johnson & Johnson$181
- Lilly USA, LLC$122
- Bayer$108
- plus $919 from 24 others
What the payments were for
- Food & beverage$2,312100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $513 |
| Amgen | 2 | $250 |
| Novo Nordisk | 6 | $220 |
| Johnson & Johnson | 8 | $181 |
| Lilly USA, LLC | 6 | $122 |
| Bayer | 5 | $108 |
| GSK | 6 | $107 |
| Halozyme Inc | 4 | $97 |
| Renalytix AI, Inc. | 5 | $96 |
| Merck | 3 | $62 |
| Indivior Inc. | 3 | $58 |
| Intra-sana Laboratories | 3 | $57 |
| AstraZeneca | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Antares Pharma, Inc. | 2 | $45 |
| Shield Therapeutics Inc | 2 | $36 |
| Medtronic | 1 | $26 |
| Abbott | 1 | $25 |
| Novartis | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Corium, LLC | 2 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,312 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $39,320 |
| MounjaroTirzepatide | 14 | $14,565 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,388 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $2,444 |
| Atorvastatin Calcium | 86 | $643 |
| Amlodipine Besylate | 66 | $429 |
| Rosuvastatin Calcium | 54 | $371 |
| Omeprazole | 20 | $361 |
| Metoprolol Succinate | 45 | $356 |
| Losartan Potassium | 58 | $251 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 26 | $231 |
| Levothyroxine Sodium | 20 | $203 |
| Metformin Hcl | 37 | $192 |
| Ezetimibe | 13 | $184 |
| Gabapentin | 13 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $220 | $39,32035 claims |
| Lilly USA, LLCMounjaro | $122 | $14,56514 claims |
| GSKTrelegy Ellipta | $107 | $7,38812 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $20320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New Hyde Park
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.